Devyser Diagnostics AB (DVYSR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has a cash flow conversion efficiency ratio of 0.034x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr12.10 Million ≈ $1.30 Million USD) by net assets (Skr357.90 Million ≈ $38.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DVYSR equity to assets ratio to measure how much of total assets are equity-financed.
Devyser Diagnostics AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Devyser Diagnostics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DVYSR cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Devyser Diagnostics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Devyser Diagnostics AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wielton S.A.
WAR:WLT
|
-0.086x |
|
Keyrus SA
PA:ALKEY
|
-0.164x |
|
PYRUM INNOV.AG NA O.N.
F:PYR
|
-0.116x |
|
Odlewnie Polskie SA
WAR:ODL
|
0.063x |
|
Hanla IMS Co. Ltd
KQ:092460
|
0.030x |
|
Impact Develop
RO:IMP
|
-0.002x |
|
Tucows Inc.
TO:TC
|
-0.019x |
|
Bokusgruppen AB
ST:BOKUS
|
-0.100x |
Annual Cash Flow Conversion Efficiency for Devyser Diagnostics AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Devyser Diagnostics AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Devyser Diagnostics AB (DVYSR) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr354.30 Million ≈ $38.13 Million |
Skr8.20 Million ≈ $882.45K |
0.023x | +117.26% |
| 2024-12-31 | Skr349.00 Million ≈ $37.56 Million |
Skr-46.80 Million ≈ $-5.04 Million |
-0.134x | +25.91% |
| 2023-12-31 | Skr385.10 Million ≈ $41.44 Million |
Skr-69.70 Million ≈ $-7.50 Million |
-0.181x | -92.80% |
| 2022-12-31 | Skr431.44 Million ≈ $46.43 Million |
Skr-40.50 Million ≈ $-4.36 Million |
-0.094x | -137.32% |
| 2021-12-31 | Skr416.68 Million ≈ $44.84 Million |
Skr-16.48 Million ≈ $-1.77 Million |
-0.040x | -294.14% |
| 2020-12-31 | Skr30.77 Million ≈ $3.31 Million |
Skr627.00K ≈ $67.48K |
0.020x | -94.85% |
| 2019-12-31 | Skr37.01 Million ≈ $3.98 Million |
Skr14.63 Million ≈ $1.57 Million |
0.395x | +96.80% |
| 2018-12-31 | Skr29.97 Million ≈ $3.23 Million |
Skr6.02 Million ≈ $647.85K |
0.201x | -- |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more